Premium
CONSERVATIVE MANAGEMENT OF SQUAMOUS CELL CARCINOMA OF THE ANAL CANAL
Author(s) -
Basser R. L.,
Smith J. G.,
Worotniuk V.,
Guiney M. J.
Publication year - 1994
Publication title -
australian and new zealand journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.111
H-Index - 51
eISSN - 1445-2197
pISSN - 0004-8682
DOI - 10.1111/j.1445-2197.1994.tb04533.x
Subject(s) - medicine , radiation therapy , abdominoperineal resection , anal canal , anal carcinoma , anal cancer , surgery , carcinoma , chemotherapy , squamous carcinoma , fluorouracil , cancer , rectum , colorectal cancer
The treatment of anal carcinoma with concurrent chemo/radiotherapy has largely replaced abdominoperineal resection as the primary management. This report details the outcome of 62 patients with anal carcinoma treated at a single institution over a 10 year period, during which this approach has become the mainstay of therapy. Of the 34 patients treated with combination radiotherapy and chemotherapy (5‐fluorouracil and mitomycin‐C), 31 were evaluable and a complete response was achieved in 77%. The estimated 5 year failure‐free survival was 67% and the overall survival was 81%. The overall survival was superior to that in patients treated with radiotherapy alone. Eighty‐four per cent of patients received the treatment as planned, while the remainder had a reduction in the dose of radiation or chemotherapy due to acute toxicity. The use of combination therapy for primary management of anal carcinoma is generally well tolerated, appears to provide a treatment outcome at least equivalent to surgery, and allows preservation of anal function. Concurrent chemo/radiotherapy should be considered in the initial management of patients with anal carcinoma.